Trial Profile
Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza virus vaccines
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2013
Price :
$35
*
At a glance
- Drugs GSK 1536489A (Primary) ; Influenza virus vaccine (Primary) ; Influenza virus vaccine (Afluria) (Primary) ; Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- 22 Feb 2013 New trial record